A cohort study involving commercially insured patients, reflective of real-world scenarios, demonstrated that users of SGLT-2 inhibitors exhibited higher rates of PAD, osteomyelitis, and lower limb ulcers when compared to individuals using metformin, sulfonylureas, or thiazolidinediones. This evidence concerns the gene SLC5A2 and ulcer of lower limb.